Navigation Links
Angiotech and Symphony Medical Announce Licensing Agreement
Date:1/17/2008

iotech.com.

About Symphony Medical

Founded in 2003 and headquartered in Orange County, California, Symphony Medical is a privately held, venture-backed company developing proprietary products to address the unmet clinical needs of millions of patients suffering from heart failure and cardiac arrhythmias. The Company's products employ proprietary biocompatible polymers injected directly into specific locations of the heart during either open chest surgery or via a minimally invasive procedure. The biopolymers are engineered to achieve clinical benefit by locally modifying cardiac physiology. To find out more about Symphony Medical, please visit http://www.symphonymed.com.

FORWARD-LOOKING STATEMENTS:

Statements contained in this press release that are not based on historical fact, including without limitation statements containing the words "believes," "may," "could", "plans," "will," "estimate," "continue," "anticipates," "intends," "expects" and similar expressions, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and constitute "forward-looking information" within the meaning of applicable Canadian securities laws. All such statements are made pursuant to the "safe harbor" provisions of applicable securities legislation. Forward-looking statements may involve, but are not limited to, comments with respect to our objectives and priorities for 2008 and beyond, our strategies or future actions, our targets, our estimation of potential market size, expectations for our financial condition and the results of, or outlook for, our operations, research development and further product and drug development. Such forward-looking statements also involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, even
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
2. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
3. Angiotech to participate in RBC 2007 Healthcare Conference
4. Angiotech to participate in Bank of America 2007 Credit Conference
5. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
8. Angiotech to participate in UBS Global Life Sciences Conference
9. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
10. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... (PRWEB) July 31, 2014 The Kidney Cancer ... of its monthly news magazine, Kidney Cancer News. , ... presence on a website maintained by an international news organization. ... immediate increase in viewers.” , This month’s program highlights news ... tumors analyzed in a recent study. Kidney Cancer News ...
(Date:7/31/2014)... July 31, 2014 Sales Horizons, a ... its online sales training course – Mastering the ... sales performance. , Drawn from proven sales training programs ... Mastering the Complex Sale online sales training course is ... who has face-to-face contact with customers, like technical support, ...
(Date:7/30/2014)... , July 30, 2014  Regeneron Pharmaceuticals, Inc. ... today announced that the Companies intend to use a ... priority review voucher in connection with the Biologics License ... entitles the holder to designate a BLA for priority ... the filing date instead of the standard 10-month review. ...
(Date:7/30/2014)... Mass. , July 30, 2014  Decision ... pharmacy and medical directors in the ... drivers of biosimilar market penetration will be the ... organizations (MCOs) and the expected lower cost to ... for biosimilars that meet their pricing expectations in ...
Breaking Biology Technology:Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 2Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3
... Computing researchers at Houston,s Rice University and electronics ... announced the formation of a $2.6-million Institute for ... at 4 million Singapore dollars, aims to slash ... -- special-purpose computer chips that power everything from ...
... Presented at the 12th World Conference on Lung ... 4 /PRNewswire-FirstCall/ - YM BioSciences Inc.,(AMEX: YMI ... that identifies,develops and commercializes differentiated products for patients ... two cohorts of,the Phase I part of a ...
... 4 The Cytokine Institute (TCI), a Los,Angeles-based ... the opening of a new office in the ... measures and analyzes the effects of,chemical and toxic ... Boston-based consulting arm, Green Reach Consulting, TCI now ...
Cached Biology Technology:Rice, Nanyang Tech collaborate on sustainable nanoelectronics 2Rice, Nanyang Tech collaborate on sustainable nanoelectronics 3YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION 2YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION 3YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION 4YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION 5Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases 2
(Date:7/31/2014)... make a rational choice to be liberal or conservative? ... a matter of genetics?, Two political scientists from the ... say that neither conscious decision-making nor parental upbringing fully ... right. , A growing body of evidence shows that ... of political differences, the researchers say in the latest ...
(Date:7/31/2014)... the U.S. surgeon general issued a 101-page report about ... University published a paper breaking new ground on how ... responds when exposed to ultraviolet (UV) light. , The ... UV rays found in sunlight. This damage can lead ... , "Our paper advances foundational knowledge about how ...
(Date:7/31/2014)... Florida State University researcher found that bacteria in the ... of the oil released during the Deepwater Horizon spill ... most toxic contaminants. , In two new studies conducted ... found a species of bacteria called Colwellia ... and xylene compounds that were released as part of ...
Breaking Biology News(10 mins):Scientists find growing consensus: Political attitudes derive from body and mind 2New paper describes how DNA avoids damage from UV light 2New paper describes how DNA avoids damage from UV light 3
... This press release is available in French ... a whole lot safer for consumers, thanks to Concordia University ... substances in dairy and other products. "Even though Canada ... antibiotics in cows, until now there were no methods or ...
... basic research, Dr. Peter W. Schiller, a world-renowned peptide chemist ... at the Institut de recherches cliniques de Montral (IRCM), and ... patents awarded to the institute and covering different uses of ... Schiller,s laboratory at the IRCM. A total of ...
... OAK RIDGE, Tenn. -- A tree outside Oak Ridge ... inspiration for a discovery that may ultimately lead to ... more. Just as a breeze causes leaves, branches ... the molecular level perform hundreds of chemical processes that ...
Cached Biology News:Discovery of therapeutic peptides affecting mitochondria 2ORNL fundamental discovery casts enzymes in new light 2
RNA polymerase sigma 70 Immunogen: Recombinant, full length protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Anti-Dardarin Immunogen: Synthetic peptide from rat LRRK2. Available Date: 38814...
Rat monoclonal to UGGT ( Abpromise for all tested applications)....
... Rabbit polyclonal to MSY2/YBOX2 ( Abpromise ... Antigen: Synthetic peptide ... the C-terminus of Human MSY2/YBOX2. ... proprietary) (Peptide available ...
Biology Products: